Fig. 1.

Study overview. A, In the discovery phase, epithelial ovarian cancer (EOC) biomarker candidates were discovered based on a proteomics-based discovery study using tissue samples from an EOC conditional GEMM. B, Biomarker candidates, i.e. the plasma-detectable, orthologous human proteins detected as differentially abundant in the discovery phase were subsequently quantified in plasma samples derived from a large cohort of EOC patients and healthy controls using selected reaction monitoring (SRM). C, Finally, the most predictive biomarker candidates for the detection of EOC were selected, combined in a protein biomarker signature, and further evaluated in an independent validation set.